A RESEARCH DIGEST · THE CYTOPROTECTION RECORD
BPC-157 is a stable gastric pentadecapeptide studied for cytoprotection and tissue repair.
Three decades of preclinical work, the angiogenesis mechanism, and where compounded and 503A access actually stand — every quantitative claim drawn from the published record and cited.
What the BPC-157 record establishes
BPC-157 is a synthetic 15-amino-acid peptide — a pentadecapeptide — derived from a partial sequence of Body Protection Compound, a protein found in human gastric juice. Its authors call it a stable gastric pentadecapeptide, and three decades of preclinical work have studied it as a cytoprotective and regenerative agent. The earliest foundational paper, in 1993, reported that the peptide protected the rat liver across several injury models, including restraint stress, bile-duct and hepatic-artery ligation, and carbon-tetrachloride exposure [7]. That cytoprotection framing — protecting tissue from injury — has organized the literature ever since.
The single most cited result is mechanical. In a fully transected rat Achilles tendon, BPC-157 accelerated healing across biomechanical, functional, microscopic, and macroscopic measures, and stimulated tendocyte outgrowth in cultured rat cells [1]. The doses were small — 10 micrograms, 10 nanograms, or even 10 picograms per rat, given once daily intraperitoneally — and the recovery was reproducible against untreated controls. The original gastric work is just as concrete: in rats, BPC 157 reduced gastric-ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming intragastric and an ulcer-formation inhibition ratio of 45.7 to 65.6 percent at the higher doses studied [4].
What ties these results together is a vascular mechanism. BPC-157 is pro-angiogenic: it up-regulates the VEGFR2 receptor and promotes its internalization, with downstream VEGFR2-Akt-eNOS signaling that drives new blood-vessel formation [3]. Read the BPC-157 mechanism of action for the full pathway, or the BPC-157 gut healing research for the gastric-cytoprotection lineage where the story began.
BPC-157 peptide: identity and structure
The BPC-157 peptide has a fixed identity. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — fifteen residues, molecular formula C62H98N16O22, molecular weight approximately 1419.53 daltons, CAS number 137525-51-0. It is often supplied as the acetate salt. The peptide is a synthetic stable fragment, not a naturally circulating hormone; the parent Body Protection Compound is the gastric-juice protein, and BPC-157 is the engineered fragment derived from it.
The "stable gastric" descriptor is load-bearing. The authors report the peptide is stable in human gastric juice, which is the rationale behind research interest in oral and peroral administration — a fragility that defeats most peptides given by mouth. That stability is a preclinical observation, not a validated human oral-delivery claim; formal human oral pharmacokinetics have not been established.
Where the human evidence actually stands
The honest summary is short. As of 2025 reviews, only three small human pilot studies exist: a two-participant intravenous safety pilot, an intra-articular knee-pain case series, and a twelve-patient intravesical interstitial-cystitis pilot [8][13]. One historical industrial development program — the designations PL 14736 and PLD-116 — reported BPC-157 was safe in early inflammatory-bowel-disease trials, but large, rigorous, controlled human efficacy trials are lacking.
This is the register the site keeps. The animal record is broad and, within the work of its principal research group, reproducible; the human record is three pilot studies. A 2025 narrative review concluded that despite broad preclinical support, BPC-157 should be considered investigational and used with caution, given limited human data, regulatory controversy, and non-regulated availability [9]. BPC-157 is not an FDA-approved drug. For the regulatory picture — FDA non-approval, the 2023 503A bulk-substance category, and how compounded access works in general — see the BPC-157 legal status and 503A category page.
What does BPC-157 do in the body?
In animal models, BPC-157 acts as a cytoprotective peptide whose repair effects are most consistently linked to angiogenesis through VEGFR2-Akt-eNOS signaling, alongside nitric-oxide-system modulation and effects on several other pathways [3][5]. It is described as a brain-gut-axis mediator: rodent work reports modulation of serotonergic and dopaminergic systems and engagement of the FAK-paxillin, Egr-1, NAB2, and JAK-2 pathways [5]. These are findings in cells and animals; subjective human effects are not established.
Is BPC-157 a growth hormone?
No. BPC-157 is a 15-amino-acid peptide derived from a gastric-juice protein, not a growth hormone. In tendon-fibroblast studies it up-regulated the growth-hormone receptor — mRNA and protein — rather than acting as the hormone itself [1]. The distinction matters: the peptide appears to sensitize tissue to growth-hormone signaling in those models, which is a different claim from being an anabolic hormone.